|
| |
LECTURES
|
Current Trends in Lung and Head & Neck Cancers
March 7, 2008
Atlanta, GA
- Adjuvant Therapy for NSCLC: Where Are We in 2008?
- Combined-Modality Therapy for Stage III NSCLC
- State of the Art in Advanced NSCLC
- What’s New With Angiogenesis Inhibitors in NSCLC?
- Recent Developments With EGFR Inhibition
- Pharmacogenomic Customization of Lung Cancer Therapy
- Novel Agents in Development for NSCLC
- Head and Neck Cancer: Current Clinical Data in 2008
- 2008 Controversies in Head and Neck Cancer
|
|
|
Eighth International Lung Cancer Congress
- Targeting Angiogenesis in First- and Second-line Therapy of Lung Cancer
- Staging
- New Targeted Approaches to Second- and Third-line Therapy of NSCLC
- Screening
- EGFR-Targeted Therapies
- Treatment of Stage III NSCLC
- Treatment of Early-Stage NSCLC
- Personalized Approaches to the Treatment of Lung Cancer
- Cooperative Group Strategies: Roundtable Discussion on First- and Second-line Therapies of Advanced NSCLC and Limited and Extensive SCLC
- Special Populations
- SCLC and Mesothelioma
|
|
|
Emerging Pathways With Therapeutic Potential in Cancer
June 1, 2007
Chicago, IL
- Targeting Signaling Pathways as a Core Strategy for Inhibiting Cancer Cell Growth
- Clinical Development of Agents Targeting the MAP/MEK and PI3K/Akt Pathways: Key Regulators of Proliferation and Survival in Cancer
- Novel Strategies to Inhibit Signaling Through VEGF Receptor in the Treatment of Cancer
- Targeted Immunotherapy for Lung Cancer
- Potential Immunologic Targets in Melanoma
- Combining Targeted Agents in Solid Tumors: Will Horizontal or Vertical Inhibition Improve the Therapeutic Index in Cancer?
|
|
Early-Stage NSCLC Module
- Early Stage NSCLC
- Introduction and Adjuvant Therapy for Resectable Lung Cancer
- Adjuvant Therapy for NSCLC: Implications of the ANITA Trial on the Present Data
|
|
|
| |
PUBLICATIONS
|
 |
Vol. 2, No. 6
1 AMA
PRA Category 1 Credit™
Expiration date: January 17, 2009
- Current Status of Antiangiogenesis Therapy of Colorectal Cancer: Timing and Duration of Therapy
- Combined Modality Therapy in Early-Stage Non–Small-Cell Lung Cancer: The Potential and Future Role of Antiangiogenic Agents
- Targeting the Tumor Microenvironment
|
|
 |
Vol. 8, No. 8
1 AMA
PRA Category 1 Credit™
Expiration date: December 7, 2008
- Targeted Agents in Non–Small-Cell Lung Cancer: Novel Agents, Novel Settings
- Phase III Trial of First-line Gemcitabine/Cisplatin/Bevacizumab in Advanced Nonsquamous NSCLC
- Phase III Trial of Gefitinib Compared to Docetaxel in Patients With Previously Treated Advanced NSCLC
- Phase II Trial of First-line Erlotinib in Patients With Advanced or Metastatic NSCLC
- Phase II Trial of First-line XL647 in Patients With NSCLC Enriched for Sensitivity to EGFR TKI
- Ongoing Phase II/III Trials of Antiangiogenic Agents in NSCLC
|
|
 |
December 2007
1 AMA
PRA Category 1 Credit™
Expiration date: December 7, 2008
- Molecular Pathogenesis of Non–Small-Cell Lung Cancer
- Individualizing Therapies in Non–Small-Cell Lung Cancer
Based on Tumor Biology and Patient Characteristics
- Optimizing the Use of EGFR Inhibitors in Patients With
Non–Small-Cell Lung Cancer
- Integration of Antiangiogenic Agents Into Treatment Paradigms
for Non–Small-Cell Lung Cancer
- Quality of Life and Adverse Events Associated With Targeted
Therapy in Non–Small-Cell Lung Cancer
- New Therapeutic Agents for Non–Small-Cell Lung Cancer
|
|
 |
November 2007
1 AMA
PRA Category 1 Credit™
Expiration date: November 20, 2008
- Targeting Signaling Pathways to Inhibit Cancer Growth
- Targeting the MAP/MEK and PI3K/Akt Pathways
- Novel Small-Molecular Inhibitors Targeting VEGFR in Breast Cancer
- Vaccines in Lung Cancer
- Novel Immunologic Targets in Metastatic Melanoma
- Combining Targeted Agents to Improve Therapeutic Efficacy
|
|
|
 |
Accreditation
Physicians’ Education Resource is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. |
|
Disclosure Policy
It is the policy of Physicians’ Education Resource
to ensure balance, independence, objectivity, and scientific rigor in all
of its educational activities. |
|
Privacy Policy
Physicians’ Education Resource (PER) makes reasonable efforts to ensure that privacy issues are handled responsibly. PER does not sell or share your information with other organizations that are not directly involved in this process. If you have further concerns, you may contact us at (888) 949-0045. |
|
